The Future of DOR-Stahla-Mab and Lendatnib

The adverse reactions to DOR-Stahla-Mab and Lendatnib are predictable. So again, you have other options in that begs the question why it's an uncertain opportunity in the front line until there is a survival advantage. And we're really hammering this hard. But all of the phase 3s are in cervix and endometrial, excuse me, cervix and ovary. We're going to do an ADC with a HER2 directed antibody drug conjugate at least I hope she will be tres2zumabduruxican.